$USIO

Usio Inc (USIO) Q2 Earnings and Revenues Top Estimates

Usio Inc (USIO) reported Q2 adjusted EPS of $0.01, versus a Zacks consensus loss of $0.01 per share, compared with a year-ago loss of $0.01. Revenue rose to $23.68M for the quarter ended June 2026, slightly above the $23.61M estimate. For next quarter, consensus calls for EPS of -$0.01 on $23.16M revenue.

Original reporting
Published Aug 12, 2026, 9:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 6:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$USIO
Bullish
medium confidence
Mentioned
$USIO
Relevance
7/10
alphai data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$USIOBullishMed
01

Why it matters

USIO’s EPS and revenue beats can drive a positive immediate reaction, but the article emphasizes that sustainability depends on management commentary and subsequent changes to near-term and full-year consensus estimates.

02

Market read

Traders get a fresh datapoint from the just-released quarter, but forward expectations still appear weak in the article’s stated consensus outlook.

03

What to watch

Estimate revisions were described as mixed ahead of the release, so traders may fade the beat if management commentary does not improve the forward outlook.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session reaction to just-released Q2 results

Background

The article summarizes USIO’s Q2 earnings and revenue results versus Zacks consensus and discusses what to watch next via earnings outlook and estimate revisions.

Company-level read

Ticker impact

$USIOBullishMedium confidence
Context

USIO reported Q2 EPS of $0.01, beating the consensus loss of $0.01, and revenues of $23.68M slightly above estimates.

Expected impact

Likely short-term support from the EPS and revenue beats, with direction next driven by guidance and revised consensus for coming quarters.

Evidence & confidence

The article provides the beat vs consensus and notes the stock’s near-term path will depend on earnings-call commentary and how estimates change after the release.

Market effects

Limited sector read-through; the article frames USIO within financial transaction services but provides no sector-wide catalyst.

No regional spillover discussed beyond USIO’s relative performance versus the S&P 500.

No global macro or cross-border driver mentioned.

Counterpoint

Despite the headline beat, the company is still near break-even and the article’s own outlook remains negative on consensus EPS for the coming quarter and fiscal year.

Key entities

  • Usio Inc

    Reported Q2 EPS of $0.01 (vs consensus loss of $0.01) and revenues of $23.68M (slightly above consensus).

Related articles

$USIOMed

Usio (USIO) Q2 2026 Earnings Call Transcript

Usio (USIO) reported Q2 2026 revenue of $23.7M, up 19%, with net income of $280K. Key growth areas include credit card (28%) and ACH (21%). The company raised fiscal 2026 revenue guidance to 14-16% growth. Management highlighted PayFac's 43% growth and upcoming Usio Ion platform rollout, expected to increase daily cash float to $300M.

$USIOHigh

Usio, Inc. (USIO): Results of Operations and Financial Condition

Usio, Inc. (USIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_973961.htm EXHIBIT 99.1 ex_973961.htm Exhibit 99.1 Usio Announces Second Quarter 2026 Financial Results Revenue, Earnings per Share, and Adjusted EBITDA 1 beat Consensus Estimates Revenue up 19% , Adjusted EBITDA 1 up 128% Raises Fiscal 2026 Revenue Guidance, Revenue

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.